SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Arbutus Biopharma Corp

(Name of Issuer)

Common Shares, without par value

(Title of Class of Securities)

(CUSIP Number)

09/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☑ Rule 13d-1(c)
☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Whitefort Capital Master Fund, LP	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 15,794,261.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 15,794,261.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 8.0 %		
12	Type of Reporting Person (See Instructions) PN		

Comment for Type of Reporting Person: The Reporting Persons (as defined below) initially filed a Schedule 13G with respect to the securities of the Issuer on September 11, 2023. Subsequently, on May 2, 2024, the Reporting Persons' investment intent changed with respect to the securities of the Issuer and the Reporting Persons filed a Schedule 13D on May 9, 2024 in accordance with Rule 13d-1(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). As of September 4, 2026, the Reporting Persons no longer held securities of the Issuer with a purpose or effect of changing or influencing control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect. Accordingly, the Reporting Persons are filing this statement on Schedule 13G pursuant to Rule 13d-1(c) of the Exchange Act in accordance with Rule 13d-1(h) of the Exchange Act.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Whitefort Capital GP, LLC		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 15,794,261.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 15,794,261.00	

9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 8.0 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Whitefort Capital Management, LP		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 15,794,261.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 15,794,261.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 8.0 %		
12	Type of Reporting Person (See Instructions) IA, PN		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Whitefort Capital Management GP, LLC		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 15,794,261.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 15,794,261.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 8.0 %		
12	Type of Reporting Person (See Instructions) OO		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons David Salanic		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization FRANCE		
Number of Shares Beneficially Owned by Each Reporting	5	Sole Voting Power 0.00	
	6	Shared Voting Power	

Person With:	7	15,794,261.00 Sole Dispositive Power 0.00
	8	Shared Dispositive Power 15,794,261.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 8.0 %	
12	Type of Reporting Person (See Instructions) HC, IN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Joseph Kaplan	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 15,794,261.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 15,794,261.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 15,794,261.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 8.0 %	
12	Type of Reporting Person (See Instructions)	

HC, IN

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Arbutus Biopharma Corp

(b) Address of issuer's principal executive offices:

701 VETERANS CIRCLE, WARMINSTER, PA 18974

Item 2.

(a) Name of person filing:

This statement is filed by: (i) Whitefort Capital Master Fund, LP, a Cayman Islands exempted limited partnership ("Whitefort Master Fund"); (ii) Whitefort Capital GP, LLC, a Delaware limited liability company ("Whitefort Master GP"), as the general partner of Whitefort Master Fund; (iii) Whitefort Capital Management, LP, a Delaware limited partnership ("Whitefort Management"), as the investment manager of Whitefort Master Fund; (iv) Whitefort Capital Management GP, LLC, a Delaware limited liability company ("Whitefort GP"), as the general partner of Whitefort Management; (v) David Salanic, as a Co-Managing Partner of Whitefort Management and a Co-Managing Member of each of Whitefort Master GP and Whitefort GP; and (vi) Joseph Kaplan, as a Co-Managing Partner of Whitefort Management and a Co-Managing Member of each of Whitefort Master GP and Whitefort GP. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

(b) Address or principal business office or, if none, residence:

The address of the principal office of Whitefort Master Fund is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008 Cayman Islands. The address of the principal office of each of Whitefort Master GP, Whitefort Management, Whitefort GP and Messrs. Salanic and Kaplan is 12 East 49th Street, 40th Floor, New York, New York 10017.

(c) Citizenship:

Whitefort Master Fund is organized under the laws of the Cayman Islands. Each of Whitefort Master GP, Whitefort Management and Whitefort GP is organized under the laws of the State of Delaware. Mr. Salanic is a citizen of France. Mr. Kaplan is a citizen of the United States of America.

(d) Title of class of securities:

Common Shares, without par value

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of the date hereof: (i) Whitefort Master Fund directly beneficially owns 15,794,261 Shares; (ii) Whitefort Master GP, as the general partner of Whitefort Master Fund, may be deemed to beneficially own the 15,794,261 Shares beneficially owned directly by Whitefort Master Fund; (iii) Whitefort Management, as the investment manager of Whitefort Master Fund, may be deemed to beneficially own the 15,794,261 Shares beneficially owned directly by Whitefort Master Fund; (iv) Whitefort GP, as the general partner of Whitefort Management, may be deemed to beneficially own the 15,794,261 Shares beneficially owned directly by Whitefort Master Fund; (v) Mr. Salanic, as a Co-Managing Partner of Whitefort Management and a Co-Managing Member of each of Whitefort Master GP and Whitefort GP, may be deemed to beneficially own the 15,794,261 Shares beneficially owned directly by Whitefort Master Fund; and (vi) Mr. Kaplan, as a Co-Managing Partner of Whitefort Management and a Co-Managing Member of each of Whitefort Master GP and Whitefort GP, may be deemed to beneficially own the 15,794,261 Shares beneficially owned directly by Whitefort Master Fund. The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Percent of class:

(b) The following percentages are based on 198,105,743 Shares outstanding as of August 19, 2026, which is the total number of Shares outstanding as reported in the Issuer's tender offer statement on Schedule TO filed with the Securities and Exchange Commission on August 24, 2026. As of the date hereof, (i) Whitefort Master Fund beneficially owns approximately 8.0% of the outstanding Shares, (ii) Whitefort Master GP may be deemed to beneficially own approximately 8.0% of the outstanding Shares, (iii) Whitefort Management may be deemed to beneficially own approximately 8.0% of the outstanding Shares, (iv) Whitefort GP may be deemed to beneficially own approximately 8.0% of the outstanding Shares, (v) Mr. Salanic may be deemed to beneficially own approximately 8.0% of the outstanding Shares and (vi) Mr. Kaplan may be deemed to beneficially own approximately 8.0% of the outstanding Shares. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Whitefort Capital Master Fund, LP

Signature:	/s/ David Salanic
Name/Title:	David Salanic, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner
Date:	09/04/2026
Signature:	/s/ Joseph Kaplan
Name/Title:	Joseph Kaplan, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner
Date:	09/04/2026

Whitefort Capital GP, LLC

Signature:	/s/ David Salanic
Name/Title:	David Salanic, Co-Managing Member
Date:	09/04/2026
Signature:	/s/ Joseph Kaplan
Name/Title:	Joseph Kaplan, Co-Managing Member
Date:	09/04/2026

Whitefort Capital Management, LP

Signature:	/s/ David Salanic
Name/Title:	David Salanic, Co-Managing Partner
Date:	09/04/2026
Signature:	/s/ Joseph Kaplan
Name/Title:	Joseph Kaplan, Co-Managing Partner
Date:	09/04/2026

Whitefort Capital Management GP, LLC

Signature:	/s/ David Salanic
Name/Title:	David Salanic, Co-Managing Member
Date:	09/04/2026
Signature:	/s/ Joseph Kaplan
Name/Title:	Joseph Kaplan, Co-Managing Member
Date:	09/04/2026

David Salanic

Signature:	/s/ David Salanic
Name/Title:	David Salanic
Date:	09/04/2026

Joseph Kaplan

Signature:	/s/ Joseph Kaplan
Name/Title:	Joseph Kaplan
Date:	09/04/2026

Exhibit Information

99.1 - Joint Filing Agreement

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated September 4, 2026 with respect to the Common Shares, without par value, of Arbutus Biopharma Corporation, and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Whitefort Capital Master Fund, LP

By: /s/ David Salanic
David Salanic, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner
Date: 09/04/2026

By: /s/ Joseph Kaplan
Joseph Kaplan, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner
Date: 09/04/2026

Whitefort Capital GP, LLC

By: /s/ David Salanic
David Salanic, Co-Managing Member
Date: 09/04/2026

By: /s/ Joseph Kaplan
Joseph Kaplan, Co-Managing Member
Date: 09/04/2026

Whitefort Capital Management, LP

By: /s/ David Salanic
David Salanic, Co-Managing Partner
Date: 09/04/2026

By: /s/ Joseph Kaplan
Joseph Kaplan, Co-Managing Partner
Date: 09/04/2026

Whitefort Capital Management GP, LLC

By: /s/ David Salanic
David Salanic, Co-Managing Member
Date: 09/04/2026

By: /s/ Joseph Kaplan
Joseph Kaplan, Co-Managing Member
Date: 09/04/2026

David Salanic

By: /s/ David Salanic
David Salanic
Date: 09/04/2026

Joseph Kaplan

By: /s/ Joseph Kaplan
Joseph Kaplan
Date: 09/04/2026